Protects Against Cancer

Metformin also has potent anti-cancer properties. Numerous studies show that metformin can help ward off various types of cancer:
1. A study found that metformin users had a 55% decrease in the risk of stomach cancer compared with nonusers. [49-50]
2. A study composed of 27 clinical trials representing more than 24,000 patients found that metformin use was associated with improved overall survival rate. [51]
3. In diabetic patients with tumors, metformin administration was associated with a 30% reduction in overall tumour onsets. [52-53]
4. In diabetic patients with lung cancer, pancreatic cancer and breast cancer, metformin administration was associated with better prognosis. [54-57]
5. A cell study found that metformin inhibited tumor growth by stimulating adenosine 5′ monophosphate-activated protein kinase (AMPK). [58-59]
6. In a breast cancer model, metformin delayed the onset of carcinoma and extended lifespan. [60]
7. Several studies found that metformin was associated with reduced cancer incidence and mortality. [61-66]
8. A study found that long-term metformin use was associated with reduced risk of ovarian cancer. [67-68]
9. In diabetic patients with breast cancer, metformin treatment was associated with absence of residual invasive disease. [69-70]
10. In Taiwanese men with type 2 diabetes mellitus, metformin use was associated with a decreased risk of incident prostate cancer. [71]
11. In American diabetic patients, metformin use was associated with a reduced risk of colorectal cancer. [72]
12. In diabetic patients, metformin use was associated with a reduced risk of pancreatic cancer. [73]
13. In patients with preexisting type 2 diabetes mellitus, metformin treatment significantly reduced the risk of liver cancer by more than 80%. [74]
14. In patients with type 2 diabetes, metformin was associated with lower cancer mortality. [75]
15. In diabetic patients with colorectal cancer, metformin improved survival rate. [76]
16. In female patients with type 2 diabetes, long-term metformin use was associated with reduced risk of breast cancer. [77]